Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
3.180
-0.010 (-0.31%)
Nov 20, 2024, 4:00 PM EST - Market closed
Marker Therapeutics Revenue
Marker Therapeutics had revenue of $1.93M in the quarter ending September 30, 2024, with 647.66% growth. This brings the company's revenue in the last twelve months to $5.40M, up 79.04% year-over-year. In the year 2023, Marker Therapeutics had annual revenue of $3.31M, down -5.76%.
Revenue (ttm)
$5.40M
Revenue Growth
+79.04%
P/S Ratio
5.25
Revenue / Employee
$674,481
Employees
8
Market Cap
28.37M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.31M | -202.41K | -5.76% |
Dec 31, 2022 | 3.51M | 2.27M | 182.96% |
Dec 31, 2021 | 1.24M | 774.93K | 166.01% |
Dec 31, 2020 | 466.79K | 253.59K | 118.95% |
Dec 31, 2019 | 213.19K | 7.20K | 3.50% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Nortech Systems | 135.57M |
IRIDEX | 48.43M |
ImmuCell | 23.84M |
Tonix Pharmaceuticals Holding | 11.29M |
NeurAxis | 2.46M |
OneMedNet | 1.02M |
Pluri | 598.00K |
MRKR News
- 6 days ago - Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma - GlobeNewsWire
- 6 months ago - Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 8 months ago - Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies - GlobeNewsWire
- 8 months ago - Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results - GlobeNewsWire
- 8 months ago - Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 10 months ago - Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 - GlobeNewsWire